Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Average: 2021-2025

Historic Equity Average for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.1 billion.

  • Krystal Biotech's Equity Average rose 26.31% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 26.31%. This contributed to the annual value of $862.5 million for FY2024, which is 32.60% up from last year.
  • Latest data reveals that Krystal Biotech reported Equity Average of $1.1 billion as of Q3 2025, which was up 7.56% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Equity Average registered a high of $1.1 billion during Q3 2025, and its lowest value of $413.4 million during Q3 2021.
  • For the 3-year period, Krystal Biotech's Equity Average averaged around $818.5 million, with its median value being $819.1 million (2024).
  • As far as peak fluctuations go, Krystal Biotech's Equity Average dropped by 11.41% in 2023, and later surged by 55.95% in 2024.
  • Over the past 5 years, Krystal Biotech's Equity Average (Quarterly) stood at $500.9 million in 2021, then grew by 6.11% to $531.5 million in 2022, then surged by 44.36% to $767.3 million in 2023, then grew by 19.40% to $916.1 million in 2024, then grew by 26.31% to $1.1 billion in 2025.
  • Its Equity Average was $1.1 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $965.5 million in Q1 2025.